Ashina M, et al. Impact of fremanezumab on headache-related disability in patients with migraine and documented inadequate response to 2–4 classes of migraine preventive medications in the multicentre, randomised, placebo-controlled FOCUS study. IHC-PO-154. IHC 2019 5-8 sept. Dublin, Ierland.
‘Antisense’-oligonucleotide HTTRx verlaagt concentratie gemuteerd huntingtine
sep 2019 | Bewegingsstoornissen